News searcher
ROVI Share Buyback Program
ROVI Share Buyback Program
ROVI reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program
4 min
03 Nov, 2021
The FDA delays its decision on Risperidone ISM®
The FDA delays its decision on Risperidone ISM®
Delay in the decision on the granting of marketing authorisation for Risperidone ISM® by the U.S. Food and Drug...
2 min
21 Oct, 2021
ROVI informa del comunicado conjunto de Moderna y Takeda en relación con la investigación sobre los lotes bloqueados de la vacuna
ROVI informs about the joint statement from Moderna and Takeda on the investigation of...
Laboratorios Farmacéuticos ROVI, S.A. informs of the joint press release from Moderna and Takeda regarding the...
4 min
01 Sep, 2021
ROVI informs on the evolution of the investigation of particulate matter having been seen...
Laboratorios Farmacéuticos ROVI, S.A. has announced that a formal investigation is continuing to determine what...
2 min
29 Aug, 2021
ROVI informs on the evolution of the investigation of particulate matter having been seen...
Laboratorios Farmacéuticos ROVI, S.A. has announced that a formal investigation is continuing to determine what...
2 min
29 Aug, 2021
ROVI informs on the notification of particulate matter having been seen in certain drug...
Laboratorios Farmacéuticos ROVI, S.A. has announced that an investigation is underway in relation to the reported...
1 min
26 Aug, 2021
ROVI achieves second place in a worldwide sustainability rating
Laboratorios Farmacéuticos ROVI, S.A. achieved the second best ESG rating out of 432 companies assessed in the...
1 min
09 Aug, 2021
ROVI achieves an increase of 52% in operating income and 75% in EBITDA
Summary of financial results for the first half of 2021
6 min
28 Jul, 2021
First half 2021 results presentation
Operating income, growth figures, profitability and how our products have behaved.
0 min
28 Jul, 2021